Opiant Pharmaceuticals has entered into a multi-year contract with potential funding up to a maximum of approximately $4.6m, with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of its lead product candidate OPTN003.
Cancer Genetics and NovellusDx have signed an agreement, under which NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to approximately 49% of the equity of Cancer Genetics on a fully diluted basis.
Danish pharmaceutical firm Novo Nordisk has unveiled plans to lay off 400 jobs as part of its efforts to transform its approach on research & development (R&D).
Roivant Sciences has launched Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases.
Atomwise, a provider of Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer.
Irish drug maker Allergan has agreed to acquire US-based clinical-stage biotech company Bonti in a deal worth more than $195m.
Boehringer Ingelheim has purchased all shares of Austrian biopharmaceutical firm, ViraTherapeutics, in a deal valued at around €210m.
OncoResponse, an immunotherapy company developing a portfolio of novel antibodies for cancer, has announced the completion of a $40m series B equity financing.
Summit Therapeutics, a UK-based clinical-stage drug discovery and development company, claims to have discovered multiple new mechanism antibiotics against novel ESKAPE pathogen targets.
Fulcrum Therapeutics, a company engaged in discovery and development of small molecule therapies for the treatment of serious genetic diseases, has raised $80m in a Series B funding round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.